Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD Voice Muted In Deliberations On Appeals Of Its Decisions

This article was originally published in The Tan Sheet

Executive Summary

The National Advertising Division changes its review process to allow opposing firms some control over scheduling in the process and in resolving their disputes. The changes, recommended by ABA committees, also impose fees for both firms in appeals and allow more time for compliance with decisions.

You may also be interested in...



Prestige Brands Stands By Nix Lice 'Kill' Claims Despite NAD Objection

Prestige Brands declines to comply with NAD recommendations to discontinue “kill” claims for its Nix Ultra lice treatment product, arguing that “eliminating” lice infestation is tantamount to “killing” the bugs. In response, NAD refers the firm's ad claims to FTC.

Prestige Brands Stands By Nix Lice 'Kill' Claims Despite NAD Objection

Prestige Brands declines to comply with NAD recommendations to discontinue “kill” claims for its Nix Ultra lice treatment product, arguing that “eliminating” lice infestation is tantamount to “killing” the bugs. In response, NAD refers the firm's ad claims to FTC.

Prestige Brands Stands By Nix Lice 'Kill' Claims Despite NAD Rejection

Prestige Brands declines to comply with NAD recommendations to discontinue “kill” claims for its Nix Ultra lice treatment product, arguing that “eliminating” lice infestation is tantamount to “killing” the bugs. In response, NAD refers the firm's ad claims to FTC.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel